Drug Profile
Dendritic cell vaccine - CreaGene
Alternative Names: CreaVax-BC; CreaVax-HCC; CreaVax-HCC Inj.; CreaVax-PC; CreaVax-PC Inj.; CreaVax-RA Inj.; CreaVax-RCC; CreaVax-RCC Inj.; Dendritic cell vaccine for glioblastoma multiforme - CreaGene; Renal cell carcinoma vaccine - CreaGene/Dong-ALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Creagene
- Developer Dong-A ST; JW CreaGene
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Renal cell carcinoma
- Phase III Liver cancer
- Phase II Rheumatoid arthritis
- Phase I/II Glioblastoma; Prostate cancer
Most Recent Events
- 28 May 2021 Beroni Group in collaboration with Tella plans a clinical trial in Cancer in Japan and China
- 28 May 2021 Beroni Group signs a Memorandum of Understanding with Tella for collaboration in Cancer in Japan and China
- 24 Sep 2019 KCT0003302- updated KDM and added development lines, edited intro, changed MoA to immunostimulants